We are live on ! Find out more
FFM

Fairmount Funds Management Portfolio holdings

AUM $1.51B
1-Year Est. Return 546.08%
This Fund
S&P 500
This Quarter Est. Return
+32.66%
1 Year Est. Return
+546.08%
3 Year Est. Return
+2,136.34%
5 Year Est. Return
+8,050.66%
10 Year Est. Return
–
AUM
$1.51B
AUM Growth
+$129M
Cap. Flow
-$167M
Cap. Flow %
-11.04%
Top 10 Hldgs %
97.65%
Holding
13
New
1
Increased
1
Reduced
–
Closed
1

Top Buys

Rank Stock Value
1
VRDN icon
Viridian Therapeutics
VRDN
+$19M
2
FTH
Faeth Therapeutics
FTH
+$16.7M

Top Sells

Rank Stock Value
1
SYRE icon
Spyre Therapeutics
SYRE
+$203M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ORKA
1
Oruka Therapeutics
ORKA
$6.02B
$353M 23.31%
3,705,262
– –
DNTH icon
2
Dianthus Therapeutics
DNTH
$6.03B
$247M 16.35%
2,537,191
– –
DMRA
3
Damora Therapeutics
DMRA
$1.73B
$227M 14.98%
8,713,000
– –
COGT icon
4
Cogent Biosciences
COGT
$6.06B
$213M 14.08%
5,503,418
– –
JBIO
5
Jade Biosciences
JBIO
$1.26B
$101M 6.69%
4,553,494
– –
ELVN icon
6
Enliven Therapeutics
ELVN
$4.37B
$94.2M 6.22%
1,855,644
– –
VRDN icon
7
Viridian Therapeutics
VRDN
$2.6B
$93.5M 6.18%
5,090,928
+1,176,470
+30% +$19M
ZBIO
8
Zenas BioPharma
ZBIO
$2.15B
$59.9M 3.96%
2,359,025
– –
CBIO
9
Crescent Biopharma
CBIO
$758M
$49.5M 3.27%
2,747,866
– –
APGE icon
10
Apogee Therapeutics
APGE
$10.2B
$39.6M 2.62%
298,647
– –
FTH
11
Faeth Therapeutics
FTH
$1.01B
$18.1M 1.19%
+722,020
New +$16.7M
IKT icon
12
Inhibikase Therapeutics
IKT
$352M
$17.5M 1.16%
8,625,000
– –
SYRE icon
13
Spyre Therapeutics
SYRE
$7.69B
– –
-4,018,101
Closed -$203M

Similar funds

AWA
Arete Wealth Advisors Chicago, Illinois $1.51B AUM 33.02% 1-Year Est. Return
DAM
DLD Asset Management New York $1.51B AUM 5.32% 1-Year Est. Return
HCM
Hodges Capital Management Dallas, Texas $1.51B AUM 85.85% 1-Year Est. Return
NB
NBT Bank Norwich, New York $1.51B AUM 24.9% 1-Year Est. Return
APF
Alaska Permanent Fund Juneau, Alaska $1.51B AUM 22.23% 1-Year Est. Return
SC
Styrax Capital New York $1.52B AUM 57.44% 1-Year Est. Return
RIM
Rush Island Management New York $1.51B AUM 8.12% 1-Year Est. Return
WFA
Wellspring Financial Advisors Cleveland, Ohio $1.52B AUM 29.68% 1-Year Est. Return

Fairmount Funds Management's Q2 2026 Portfolio in Review

As of Q2 2026, Fairmount Funds Management held 13 positions worth $1.51B, up 9.3% from $1.38B the previous quarter. Its ten largest holdings account for 98% of the portfolio.

Fairmount Funds Management withdrew a net $167M in Q2 2026, closing 1 position. Its most notable exit was Spyre Therapeutics, an estimated $203M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

Against the trend, Fairmount Funds Management opened a new position in Faeth Therapeutics worth $18.1M.

  • Fairmount Funds Management's largest Q2 2026 buy was Faeth Therapeutics: 722,020 shares worth $18.1M.
  • Fairmount Funds Management added most to Viridian Therapeutics in Q2 2026, an estimated $19M increase.
  • Fairmount Funds Management fully exited Spyre Therapeutics in Q2 2026, selling an estimated $203M.
  • Fairmount Funds Management's ten largest holdings make up 98% of its $1.51B portfolio in Q2 2026.
  • Fairmount Funds Management opened 1 new position and closed 1 in Q2 2026.
  • Fairmount Funds Management's portfolio value rose 9.3% quarter-over-quarter to $1.51B.

Based on Fairmount Funds Management's 13F filing for Q2 2026, filed 14 Aug 2026.